<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3510">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03061214</url>
  </required_header>
  <id_info>
    <org_study_id>NN9535-4114</org_study_id>
    <secondary_id>U1111-1149-0432</secondary_id>
    <nct_id>NCT03061214</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT)</brief_title>
  <acronym>SUSTAIN</acronym>
  <official_title>Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes. A 30-week Randomised, Double-blind, Double-dummy, Active-controlled, Parallel-group, Multi-centre and Multi-national Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Africa, Asia, Europe and South America. The aim of the trial is
      to compare the effect of once-weekly dosing of two dose levels of semaglutide versus
      sitagliptin 100 mg once-daily on glycaemic control after 30 weeks of treatment. Subjects
      will remain on their stable pre-trial metformin.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 28, 2017</start_date>
  <completion_date type="Anticipated">November 19, 2018</completion_date>
  <primary_completion_date type="Anticipated">September 24, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c (glycosylated haemoglobin)</measure>
    <time_frame>Week 0, week 30</time_frame>
    <description>Measured in %</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>Week 0, week 30</time_frame>
    <description>Measured in kg and/or %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting plasma glucose (FPG)</measure>
    <time_frame>Week 0, week 30</time_frame>
    <description>Measured in mg/dl or other equivalent SI units</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in systolic blood pressure</measure>
    <time_frame>Week 0, week 30</time_frame>
    <description>Measured in mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in diastolic blood pressure</measure>
    <time_frame>Week 0, week 30</time_frame>
    <description>Measured in mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in patient reported outcome (PRO) questionnaire: Diabetes Treatment Satisfaction Questionnaire status (DTSQs) score</measure>
    <time_frame>Week 0, week 30</time_frame>
    <description>The DTSQs questionnaire will be used to assess subject's treatment satisfaction. This instrument contains 8 items and measures the treatment for your diabetes (including insulin, tablets and/or diet) in terms of convenience, flexibility and general feelings regarding treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects who achieve HbA1c below or equal to 6.5% (48 mmol/mol) - American Association of Clinical Endocrinologists (AACE) (yes/no)</measure>
    <time_frame>After 30 weeks</time_frame>
    <description>Proportion of subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in self-measured plasma glucose (SMPG), 7 point profile - mean 7-point profile</measure>
    <time_frame>Week 0, week 30</time_frame>
    <description>Mean glucose values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in self-measured plasma glucose (SMPG), 7 point profile - mean post-prandial increment</measure>
    <time_frame>Week 0, week 30</time_frame>
    <description>Mean glucose values over all meals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body mass index (BMI)</measure>
    <time_frame>Week 0, week 30</time_frame>
    <description>Measured in kg/m^2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in waist circumference</measure>
    <time_frame>Week 0, week 30</time_frame>
    <description>Measured in cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in patient reported outcome (PRO) questionnaire: SF-36v2(TM) score</measure>
    <time_frame>Week 0, week 30</time_frame>
    <description>Short Form 36 v2.0 acute (SF-36) is a 36-item, patient-reported survey of patient health. SF-36 measures the subject's overall Health Related Quality of Life on 8 domains: physical functioning, role functioning, bodily pain, general health, vitality, social functioning, role emotional and mental health</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects who achieve HbA1c below or equal to 7.0% (53 mmol/mol) - American Diabetes Association (ADA) target (yes/no)</measure>
    <time_frame>Week 30</time_frame>
    <description>Proportion of subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achievement of weight loss greater than or equal to 5%</measure>
    <time_frame>Week 30</time_frame>
    <description>Proportion of subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achievement of weight loss greater than or equal to 10%</measure>
    <time_frame>Week 30</time_frame>
    <description>Proportion of subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects who achieve HbA1c below 7.0% (53 mmol/mol) without severe or blood glucose (BG) confirmed symptomatic hypoglycaemia and no weight gain</measure>
    <time_frame>Week 30</time_frame>
    <description>Proportion of subjects - fulfilling both criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment emergent adverse events (TEAEs)</measure>
    <time_frame>Week 0 - week 30</time_frame>
    <description>Count and % of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes</measure>
    <time_frame>Week 0 - week 30</time_frame>
    <description>Count of events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting blood lipids: total cholesterol</measure>
    <time_frame>Week 0, week 30</time_frame>
    <description>Measured in mg/dl or other equivalent SI units</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting blood lipids: low density lipoprotein (LDL) cholesterol</measure>
    <time_frame>Week 0, week 30</time_frame>
    <description>Measured in mg/dl or other equivalent SI units</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting blood lipids: very low density lipoprotein (VLDL) cholesterol</measure>
    <time_frame>Week 0, week 30</time_frame>
    <description>Measured in mg/dl or other equivalent SI units</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting blood lipids: high density lipoprotein (HDL) cholesterol</measure>
    <time_frame>Week 0, week 30</time_frame>
    <description>Measured in mg/dl or other equivalent SI units</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting blood lipids: triglycerides</measure>
    <time_frame>Week 0, week 30</time_frame>
    <description>Measured in mg/dl or other equivalent SI units</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting blood lipids: free fatty acids</measure>
    <time_frame>Week 0, week 30</time_frame>
    <description>Measured in mg/dl or other equivalent SI units</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1050</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Semaglutide 0.5 mg OW + sitagliptin placebo OD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Semaglutide 1 mg OW + sitagliptin placebo OD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin OD + semaglutide placebo 0.5 mg OW</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin OD + semaglutide placebo 1 mg OW</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Semaglutide 0.5 mg</intervention_name>
    <description>Up to 0.5 mg semaglutide injected subcutaneously (s.c., under the skin) once-weekly (OW) for 30 weeks</description>
    <arm_group_label>Semaglutide 0.5 mg OW + sitagliptin placebo OD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Semaglutide 1.0 mg</intervention_name>
    <description>Up to 1.0 mg semaglutide injected subcutaneously once-weekly for 30 weeks</description>
    <arm_group_label>Semaglutide 1 mg OW + sitagliptin placebo OD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin placebo</intervention_name>
    <description>Sitagliptin placebo tablets taken once-daily for 30 weeks</description>
    <arm_group_label>Semaglutide 0.5 mg OW + sitagliptin placebo OD</arm_group_label>
    <arm_group_label>Semaglutide 1 mg OW + sitagliptin placebo OD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>100 mg sitagliptin tablets taken once-daily for 30 weeks</description>
    <arm_group_label>Sitagliptin OD + semaglutide placebo 0.5 mg OW</arm_group_label>
    <arm_group_label>Sitagliptin OD + semaglutide placebo 1 mg OW</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Semaglutide placebo 0.5 mg</intervention_name>
    <description>Semaglutide placebo (0.5 mg) injected subcutaneously once-weekly for 30 weeks</description>
    <arm_group_label>Sitagliptin OD + semaglutide placebo 0.5 mg OW</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Semaglutide placebo 1.0 mg</intervention_name>
    <description>Semaglutide placebo (1.0 mg) injected subcutaneously once-weekly for 30 weeks</description>
    <arm_group_label>Sitagliptin OD + semaglutide placebo 1 mg OW</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent obtained before any trial-related activities. Trial-related
             activities are any procedures that are carried out as part of the trial, including
             activities to determine suitability for the trial

          -  Male or female, age equal to or above 18 years at the time of signing informed
             consent

          -  Subjects diagnosed with type 2 diabetes and on stable treatment in a period of 60
             days prior to screening with metformin equal to or above 1500 mg (or maximum
             tolerated dose equal to or above 1000 mg). Stable is defined as unchanged medication
             and unchanged daily dose

          -  HbA1c 7.0 - 10.5 % (53-91 mmol/mol) (both inclusive)

        Exclusion Criteria:

          -  Female who is pregnant, breast-feeding or intends to become pregnant or is of
             childbearing potential not using an adequate contraceptive method throughout the
             trial including the 5 week follow-up period (adequate contraceptive measure as
             required by local regulation or practice)

          -  Any disorder which, in the opinion of the investigator, might jeopardise subject's
             safety or compliance with the protocol

          -  Treatment with glucose lowering agent(s) other than stated in the inclusion criteria
             in a period of 60 days before screening. An exception is short-term treatment (equal
             to or below 7 days in total) with insulin in connection with inter-current illness

          -  History of chronic or idiopathic acute pancreatitis

          -  Screening calcitonin value equal to or above 50 ng/L (pg/mL)

          -  Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine
             neoplasia syndrome type 2 (MEN 2)

          -  Impaired renal function defined as estimated glomerular filtration rate (eGFR) below
             60 ml/min/1.73 m^2 per modification of diet in renal disease (MDRD) formula (4
             variable version)

          -  Acute coronary or cerebrovascular event within 90 days before randomisation

          -  Heart failure, New York Heart Association (NYHA) class IV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novo Nordisk</last_name>
    <email>clinicaltrials@novonordisk.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 6, 2017</lastchanged_date>
  <firstreceived_date>February 17, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>According to the Novo Nordisk disclosure commitment on novonordisk-trials.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
